
Ebola drug ZMapp gets orphan status in Europe
Right on the heels of a fast track designation from the FDA, San Diego startup Mapp Biopharmaceutical gets orphan drug status from European regulators for its Ebola drug, ZMapp.
Right on the heels of a fast track designation from the FDA, San Diego startup Mapp Biopharmaceutical gets orphan drug status from European regulators for its Ebola drug, ZMapp.